Jonathan Biller's most recent trade in Vertex Pharmaceuticals, Inc. was a trade of 1,657 Common Stock done at an average price of $455.1 . Disclosure was reported to the exchange on Feb. 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 455.06 per share. | 14 Feb 2025 | 1,657 | 17,606 (0%) | 0% | 455.1 | 754,034 | Common Stock |
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 1,504 | 19,263 (0%) | 0% | 463.5 | 697,044 | Common Stock |
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 4,437 | 20,767 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 459.87 per share. | 10 Feb 2025 | 3,433 | 16,330 (0%) | 0% | 459.9 | 1,578,734 | Common Stock |
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 1,632 | 19,763 (0%) | 0% | 468.0 | 763,743 | Common Stock |
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 4,744 | 21,395 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 461.66 per share. | 01 Oct 2024 | 999 | 16,651 (0%) | 0% | 461.7 | 461,198 | Common Stock |
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 466.84 per share. | 01 Oct 2024 | 630 | 17,650 (0%) | 0% | 466.8 | 294,109 | Common Stock |
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 418.77 per share. | 09 Feb 2024 | 1,738 | 18,280 (0%) | 0% | 418.8 | 727,822 | Common Stock |
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 1,588 | 20,018 (0%) | 0% | 422.7 | 671,311 | Common Stock |
| Vertex Pharma | Biller Jonathan | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 6,294 | 16,863 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Biller Jonathan | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 4,743 | 21,606 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jonathan Biller | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 6,293 | 11,587 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Jonathan Biller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 41,000 | 41,000 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Jonathan Biller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,500 | 11,500 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Jonathan Biller | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 8,523 | 8,522 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Jonathan Biller | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 8,523 | 25,641 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jonathan Biller | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 18 Feb 2022 | 2,688 | 22,953 (0%) | 0% | 29.1 | 78,167 | Common stock |
| Agios Pharmaceuticals Inc | Jonathan Biller | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 3,667 | 7,333 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Jonathan Biller | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 3,667 | 18,467 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jonathan Biller | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 1,349 | 17,118 (0%) | 0% | 31.4 | 42,392 | Common stock |
| Agios Pharmaceuticals Inc | Jonathan Biller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 44,000 | 44,000 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Jonathan Biller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Restricted stock units |